We investigate the protective effect of curcumin (CU) on the hepatic ultrastructural damage induced by cisplatin in mice. 18 adult Kunming mice were randomly divided into normal saline (NS) group, cisplatin treatment group (CP) and CU + CP group (n = 6 for each group). Mice in control group and CP group were administered with NS (20 mL/kg/day) and CU + CP group were i.p injected with CU (200 mg/kg/day) for 10 days. Then cisplatin (50 mg/kg/day) was injected in mice of CP group and CU + CP group, while those in control group were given the same volume of NS. Five days after injection all mice were killed and liver dissected. The hepatic morphological structures were observed under light microscope and transmission electron microscope. The results indicated that CU alleviated the hepatic histopathological damages induced by cisplatin, which included declined body weight, vacuolated cytoplasm and blurred liver trabecular structure. Moreover, no hepatic ultrastructural damages were observed in the CU protective group with condensed and marginated nuclear chromatin, bile canaliculi outstreched and bile deposited.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/01913123.2014.933289 | DOI Listing |
Adv Sci (Weinh)
January 2025
Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, Jiangsu Provincial Key Medical Discipline, Nanjing University Medical School, Nanjing, 210008, China.
Cisplatin-induced ototoxicity is attributed to the aberrant accumulation of reactive oxygen species (ROS) within the inner ear. Antioxidants represented by α-lipoic acid (ALA) have been demonstrated to scavenge ROS in the cochlea, while effective delivery of these agents in vivo remains a major challenge. Here, a novel polydopamine (PDA) nanogel decorated adhesive and responsive hierarchical microcarriers for controllable is presented ALA delivery and deafness prevention.
View Article and Find Full Text PDFAm J Transl Res
December 2024
Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Tianjin 300070, China.
Proteinase-activated receptor-2 (PAR2) is closely linked to tumor malignancy, but its biological role in cancer remains underexplored. In this study, we assessed PAR2 expression in lung adenocarcinoma (LUAD) and normal lung tissues, analyzed associations between clinicopathological features and survival rates, and confirmed that PAR2 promotes apoptosis resistance and reduces cisplatin-induced cytotoxicity in lung cancer cells. Using TCGA datasets, western blotting, qPCR, and immunohistochemistry (IHC), we observed a significant increase in PAR2 levels in LUAD samples compared to normal tissues (P<0.
View Article and Find Full Text PDFPLoS One
January 2025
Faculty of Allied Health Sciences, Burapha University, Chonburi, Thailand.
Cholangiocarcinoma (CCA) poses a significant healthcare challenge due to the limited effects of chemotherapeutic drugs. Natural products have gained widespread attention in cancer research according to their promising anti-cancer effects with minimal adverse side effects. This study explored the potential of Tacca chantrieri (TC), a plant rich in bioactive compounds, as a therapeutic agent for CCA.
View Article and Find Full Text PDFJ Cannabis Res
January 2025
School of Pharmacy, Pharmaceutical Sciences Department, Lebanese American University, Byblos, Lebanon.
Background: Cisplatin is an anti-cancer drug used to treat a plethora of solid tumors. However, it is associated with dose dependent nephrotoxicity limiting its use as anticancer agent.
Objective: The current study aimed to investigate the nephroprotective effect of native Lebanese Cannabis sativa in both in vitro and in vivo mice model of cisplatin-induced nephrotoxicity.
JCO Glob Oncol
January 2025
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.
Purpose: The use of short hydration (SH) to prevent cisplatin-induced nephrotoxicity lacks substantive prospective evaluation. The aim of this study was to evaluate the safety and efficacy of SH, including those with head and neck cancer (HNC) who are at higher risks of mucositis that causes diminished oral intake.
Methods: This phase II randomized noncomparative trial included patients with cancer who were scheduled to receive high-dose cisplatin (≥60 mg/m) in combination with another chemotherapy or concurrently with radiotherapy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!